Reducing hERG Inhibition in the Design of Potent and Bioavailable Indazole cGAS Inhibitors
Patrick Cyr1, Amandine Chefson1, Daniel V Sietsema2
1Ventus Therapeutics, 4800, rue Lévy #110, Saint-Laurent, H4R 2P1 QC, Canada.
Abstract:
Cyclic GMP-AMP synthase (cGAS) is a key component of the cGAS-STING innate immunity pathway's response to pathogens. Activation of cGAS triggers a cascade resulting in an increase of proinflammatory mediators, suggesting cGAS inhibition as an attractive therapeutic approach for a variety of autoimmune and neurodegenerative diseases. The medicinal chemistry optimization of tetrahydrocarboline cGAS inhibitor 3 was performed with particular emphasis on mitigating hERG activity and improving bioavailability. Meticulous control of polarity was found to be essential to access acceptable in vitro permeability and stability profiles while mitigating hERG inhibition. Compound 26 was identified as a potent cGAS inhibitor displaying favorable hERG and mouse pharmacokinetic (PK) profiles.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Basicity of Heterocyclic Aromatic Amines
